Environmental Health Economic Analysis Annotated Bibliography
Go BackDetails
Research articleAuthors
Waters HR, Foldes SS, Alesci NL and Samet J
Journal
American Journal of Public Health
Summary
This cost analysis study estimated the prevalence and costs of treated medical conditions related to secondhand smoke exposure (e.g., lung cancer and coronary heart disease) in Minnesota and found that the total annual cost of treatment was $228.7 million. The results presented a strong rationale for regulating smoking in public places and were used to support the passage of Minnesota's Freedom to Breathe Act of 2007.
Population
Nonsmokers — children and adolescents (≤ 17 years); adults (18 years +)
Health Outcomes
- Birth outcomes, Respiratory outcomes, Cancer, Cardiovascular outcomes
Health Outcome List:
- Birth outcomes (low birth weight)
- respiratory outcomes (acute lower respiratory illnesses, asthma)
- ear infection
- cancer outcomes (lung cancer)
- cardiovascular outcomes (coronary heart disease)
Environmental Agents
List of Environmental Agents:
- Air pollutants (tobacco smoke)
Source of Environmental Agents:
- Cigarette smoke (secondhand)
Economic Evaluation / Methods and Source
Type:
- Cost analysis (CA)
Cost Measures:
- Costs related to professional services
- inpatient/outpatient hospital services
- laboratory, radiology, and pathology services
- costs of prescribed pharmaceuticals for all assessed outcomes
Potential Cost Measures:
- Medical costs related to sub conditions such as "cough, phlegm, wheeze, and breathlessness among schoolchildren" and "lower level of lung function during childhood" were excluded because they could not be clearly mapped to coded medical conditions with administrative claims data. Medical costs related to SIDS were excluded because the condition leads to immediate mortality instead of treatment. Investigators also excluded costs associated with health conditions the surgeon general identified as having a "suggestive but not sufficient" causal link with exposure to secondhand smoke.
Benefits Measures:
- Not available
Potential Benefits Measures:
- Not available
Location:
- Minnesota
Models Used:
- Population Attributable Risk (PAR) equation
- Episode Treatment Group methodology (ETG codes)
Models References:
- Episode Treatment Group methodology: http://www.ncbi.nlm.nih.gov/pubmed/11143280
Methods Used:
- The authors estimated medical treatment costs related to exposure to secondhand tobacco smoke (SHS) in the state of Minnesota. To generate prevalence and cost estimates, the authors — 1) identified health conditions caused by secondhand smoke exposure; 2) determined the prevalence for each condition for Blue Cross members; 3) adjusted the treated prevalence to the state level; 4) determined the number of episodes attributable to secondhand smoke; and 5) determined the cost per episode. The authors used Episode Treatment Group (ETG) codes, applied to administrative claims data from Blue Cross, to identify individuals with an episode, and the average cost per episode, for each of the assessed health conditions for the year 2003.
Sources Used:
- Administrative claims data (Blue Cross Blue Shield of Minnesota); The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General (2006); Current Population Survey (Bureau of Labor Statistics, 2004); Health Insurance Coverage in Minnesota: Trends from 2001-2004 (Minnesota Health Access Survey, 2006); Minnesota Department of Health (2006); Agency for Health Care Research and Quality Procedures in US Hospitals (2003); Minnesota Department of Human Services; Medicare Chart Book (2006); American Cancer Society (2006); Medical Expenditure Panel Survey (MEPS) (2003); US Consumer Price Index for Medical Services (US Department of Labor, 2006); additional sources cited in publication
Economic Citation / Fundings
Citation:
- Waters HR, Foldes SS, Alesci NL and Samet J. The economic impact of exposure to secondhand smoke in Minnesota. American Journal of Public Health. 2009. 99; 4.
- Pubmed
- DOI
NIEHS Funding:
- Not available
Other Funding: Not available